Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases
Open accessAbstract
Background: Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates. Expression of CD30 has been observed in testicular cancers, and patients with CD30-expressing embryonal carcinomas have worse progression-free survival and overall survival than those with CD30-negative tumors. The objective of this study (NCT01461538) was to characterize the antitumor activity of brentuximab vedotin in patients with CD30-expressing nonlymphomatous malignancies. Enrolled patients included seven patients with relapsed or refractory germ cell tumors or metastatic sex cord stromal tumors described in this case series. Materials and Methods: Forty patients with relapsed or refractory germ cell tumors, metastatic sex cord stromal tumors, or testicular tumors were screened for CD30 expression; 14 patients had tumors that expressed CD30. Seven patients with CD30-expressing testicular cancer were enrolled in the treatment study: five patients with germ cell tumors, one patient with a Leydig cell tumor, and one patient with a Sertoli cell tumor. Patients were treated with brentuximab vedotin at initial doses of 1.8 or 2.4 mg/kg every 3 weeks. Response assessments were performed at cycles 2 and 4 and every 4 cycles thereafter while the patient was receiving treatment. Results: Two of seven patients achieved an objective response, including one durable complete response and one partial response at a single time point. Both responding patients had germ cell tumors. Treatment with brentuximab vedotin was generally well tolerated. Conclusion: Treatment of relapsed or refractory germ cell tumors with brentuximab vedotin can induce durable responses with a manageable toxicity profile. Implications for Practice: This case series of seven patients with relapsed or refractory CD30-expressing germ cell tumors (GCTs) or sex cord stromal tumors demonstrates that brentuximab vedotin has activity against GCTs and is well tolerated in heavily pretreated patients with these aggressive tumor types. One patient achieved a complete response that has been durable for almost 4 years since the discontinuation of treatment with brentuximab vedotin. Therefore, brentuximab vedotin may be a valuable option for physicians who care for this difficult-to-treat patient population.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a phase II study of seven patients with multiple relapses or cisplatin-refractory disease and CD30 overexpression, two patients had an objective response to brentuximab vedotin.
“In a phase II study, seven patients with multiple relapses or cisplatin-refractory disease and CD30 overexpression were enrolled.”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [54]
The study description identifies a phase II trial, and the Results report seven enrolled patients with CD30-expressing tumors, two of whom had objective responses. However, the Patients section defines eligibility as CD30 expression of at least 10% plus failure, refusal, or ineligibility for standard therapy; it does not establish that all seven had multiple relapses or cisplatin-refractory disease. The paper describes CD30 expression, not necessarily overexpression. (LLM, conf=0.86)
Experimental — accuracy not yet measuredOne patient had a sustained complete response.
“One patient exhibited a sustained complete response”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [54]
The other patient had a partial response.
“while the other had a partial response [54].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.594 · Cited by 1,929 · see citing works
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,528 · see citing works
Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M. A., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 1,004 · see citing works
Guidelines on Testicular Cancer: 2015 Update
Albers, P., Albrecht, W., Ferran Algaba, B., Bokemeyer, C., Cohn-Cedermark, G. E., Fizazi, K. S., Horwich, A., Laguna, M. P., Nicolai, N., & Oldenburg, J. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.044 · Cited by 667 · see citing works
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A. R., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 495 · see citing works
Self-citationMedical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 374 · see citing works
Self-citationObjective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., et al. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 356 · see citing works
Fu, L., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., Benjamin, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1795 · Cited by 346 · see citing works
BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol- resistant epitope
Schwarting, R., Gerdes, J., Dürkop, H., Falini, B., Pileri, S. A., & Stein, H. (1989) · Blood · doi:10.1182/blood.v74.5.1678.1678 · Cited by 311 · see citing works
Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., et al. (2015) · Blood · doi:10.1182/blood-2014-09-598763 · Cited by 304 · see citing works
Sutherland, M. K., Sanderson, R. J., Gordon, K. A., Andreyka, J. B., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510026200 · Cited by 296 · see citing works
Kim, Y. H., Tavallaee, M., Sundram, U. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3969 · Cited by 283 · see citing works
Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma.
Pallesen, G., & Hamilton-Dutoit, S. J. (1988) · PubMed Central · Cited by 219 · see citing works
Chen, R., Hou, J., Newman, E. M., Kim, Y., Donohue, C., Liu, X., Thomas, S. H., Forman, S. J., & Kane, S. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0036 · Cited by 217 · see citing works
Müller, P., Martin, K., Theurich, S., Schreiner, J., Savic, S., Terszowski, G., Lardinois, D., Heinzelmann-Schwarz, V. A., Schlaak, M. S., Kvasnicka, H. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0198 · Cited by 206 · see citing works
Testicular Germ Cell Tumours in Denmark 1976–1980 Pathology of 1058 Consecutive Cases
Jacobsen, G. K., Barlebo, H., Olsen, J., et al. (1984) · Acta Radiologica Oncology · doi:10.3109/02841868409136019 · Cited by 188 · see citing works
Adra, N., Abonour, R., Althouse, S. K., Albany, C., Hanna, N. H., & Einhorn, L. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5395 · Cited by 183 · see citing works
Self-citationEtiologic Factors in Testicular Germ-Cell Tumors
McGlynn, K. A., & Cook, M. B. (2009) · Future Oncology · doi:10.2217/fon.09.116 · Cited by 157 · see citing works
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C., & Gerber, H. (2007) · Blood · doi:10.1182/blood-2007-06-097014 · Cited by 117 · see citing works
Results of Treatment After Relapse From High-Dose Chemotherapy in Germ Cell Tumors
Porcu, P., Bhatia, S., Sharma, M., & Einhorn, L. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1181 · Cited by 84 · see citing works
Self-citationKier, M. G. G., Lauritsen, J., Mortensen, M. S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.09.015 · Cited by 82 · see citing works
Lorch, A., Neubauer, A., Hackenthal, M., Dieing, A., Hartmann, J. T., Rick, O., Bokemeyer, C., & Beyer, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp366 · Cited by 78 · see citing works
Feldman, D. R., Patil, S., Trinos, M. J., Carousso, M., Ginsberg, M. S., Sheinfeld, J., Bajorin, D. F., Bosl, G. J., & Motzer, R. J. (2012) · Cancer · doi:10.1002/cncr.26375 · Cited by 68 · see citing works
Self-citationClinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors
Silberstein, J. L., Bazzi, W. M., Vertosick, E., et al. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.01.104 · Cited by 59 · see citing works
Feldman, D. R., Einhorn, L. H., Quinn, D. I., Loriot, Y., Joffe, J., Vaughn, D. J., Fléchon, A., Hajdenberg, J. J., Halim, A., Zahir, H., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9934-y · Cited by 48 · see citing works
Self-citationAnti-CD30 Antibodies for Hodgkin Lymphoma
Foyil, K. V., & Bartlett, N. L. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0053-y · Cited by 47 · see citing works
Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death
Gardai, S. J., Epp, A., & Law, C. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2469 · Cited by 47 · see citing works
Giannatempo, P., Paolini, B., Miceli, R., Raggi, D., Nicolai, N., Farè, E., Catanzaro, M. A., Biasoni, D., Torelli, T., Stagni, S., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.04.057 · Cited by 37 · see citing works
Cao, A., Heiser, R. A., Law, C., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4914 · Cited by 29 · see citing works
Kim, Y. H., Whittaker, S. J., Horwitz, S. M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.182.182 · Cited by 18 · see citing works
Current chemotherapeutic approaches for recurrent or refractory germ cell tumors
O’Carrigan, B., & Grimison, P. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.09.007 · Cited by 14 · see citing works
Fu, L., Zhang, X., Emmerton, K. K., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-3694 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Ashkar, R., Feldman, D. R., Adra, N., Zaid, M. A., Funt, S. A., Althouse, S. K., Perkins, S. M., Snow, C. I., Lazzara, K. M., Sego, L. M., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01134-1 · Cited by 16 · see citing works
Self-citationEvmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024) · Cancers · doi:10.3390/cancers16020428 · Cited by 11 · see citing works
“One patient exhibited a sustained complete response while the other had a partial response [54].”
Background
- Authors
- Albany, C., Einhorn, L., Garbo, L., Boyd, T., Josephson, N., & Feldman, D. R.
- Affiliations
- Indiana University (US)
- New York Oncology Hematology (US)
- Virginia Mason Memorial (US)
- Seagen (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Albany, Costantine
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-08
- Volume
- 23
- Issue
- 3
- Pages
- 316-323
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC5905693
- OpenAlex
- W2771821139
- Cited by
- 51
- References
- 33
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 5
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- brentuximab vedotin, CD30, germ cell tumors, sex cord-stromal tumors, testicular cancer, embryonal carcinoma, relapsed/refractory cancer, anticancer activity, treatment toxicity, Sertoli cell tumor, Leydig cell tumor, complete response, metastatic cancer, targeted therapy
- MeSH terms
- Brentuximab Vedotin, Adult, Antineoplastic Agents, Drug Administration Schedule, Humans, Immunologic Factors, Male, Middle Aged, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Remission Induction, Treatment Outcome, Ki-1 Antigen, Sex Cord-Gonadal Stromal Tumors, Immunoconjugates, Drug Resistance, Neoplasm, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
